ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
April 13, 2021Innovent Biologics, Inc. announced with Eli Lilly and Company that the results of the Phase 3 ORIENT-3 study were released in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021. -
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer
January 12, 2021Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and ...
Pharma Sources Insight January 2025
